Cargando…

Cost-utility analysis of de-escalating biological disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis

OBJECTIVE: Recent guideline updates have suggested de-escalating DMARDs when patients with rheumatoid arthritis achieve remission or low disease activity. We aim to evaluate whether it is cost-effective to de-escalate the biological form of DMARDs (bDMARDs). METHODS: Using a Markov model, we perform...

Descripción completa

Detalles Bibliográficos
Autores principales:	Birkner, Benjamin, Rech, Jürgen, Stargardt, Tom
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2020
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6939943/ https://www.ncbi.nlm.nih.gov/pubmed/31895926 http://dx.doi.org/10.1371/journal.pone.0226754

Ejemplares similares

Utilizing biologic disease-modifying anti-rheumatic treatment sequences to subphenotype rheumatoid arthritis
por: Das, Priyam, et al.
Publicado: (2023)

Effectiveness of sequential biologic and targeted disease modifying anti-rheumatic drugs for rheumatoid arthritis
por: Zhao, Sizheng Steven, et al.
Publicado: (2022)

Effect of biologics and targeted synthetic disease-modifying anti-rheumatic drugs on fatigue in rheumatoid arthritis
por: Choy, Ernest H
Publicado: (2019)

Decreased chronic kidney disease in rheumatoid arthritis in the era of biologic disease-modifying anti-rheumatic drugs
por: Hanaoka, Hironari, et al.
Publicado: (2022)

Therapeutic Utility and Adverse Effects of Biologic Disease-Modifying Anti-Rheumatic Drugs in Inflammatory Arthritis
por: Min, Hong Ki, et al.
Publicado: (2022)

Risk factors for bone loss in patients with rheumatoid arthritis treated with biologic disease-modifying anti-rheumatic drugs
por: Tawaratsumida, Hiroki, et al.
Publicado: (2017)

Effect of Biological Disease-modifying Anti-rheumatic Drugs on Airway and Interstitial Lung Disease in Patients with Rheumatoid Arthritis
por: Kurata, Izumi, et al.
Publicado: (2019)

Outcomes with Biological Disease-Modifying Anti-Rheumatic Drugs (bDMARDs) in Older Patients Treated for Rheumatoid Arthritis
por: Akter, Ripa, et al.
Publicado: (2020)

Biological targets in the treatment of rheumatoid arthritis: a comprehensive review of current and in-development biological disease modifying anti-rheumatic drugs
por: Kukar, Manil, et al.
Publicado: (2009)

How do clinicians prescribe bridging glucocorticoids in people starting or escalating disease-modifying anti-rheumatic drugs for rheumatoid arthritis: a service evaluation survey
por: Prior, James A, et al.
Publicado: (2023)

Disease-modifying anti-rheumatic drugs improve the cardiovascular profile in patients with rheumatoid arthritis
por: Giachi, Andrea, et al.
Publicado: (2022)

Factors associated with radiographic progression in rheumatoid arthritis starting biological diseases modifying anti-rheumatic drugs (bDMARDs)
por: Adami, Giovanni, et al.
Publicado: (2023)

Response to Biologic Disease-Modifying Anti-Rheumatic Drugs after Discontinuation of Anti-Tumor Necrosis Factor Alpha Agents for Rheumatoid Arthritis
por: Bergman, Martin J., et al.
Publicado: (2014)

Exploring the treatment burden of disease-modifying anti-rheumatic drug monitoring in people with rheumatoid arthritis
por: Ryan, Sarah, et al.
Publicado: (2023)

Disease-modifying anti-rheumatic drugs associated with different diabetes risks in patients with rheumatoid arthritis
por: Su, Yu-Jih, et al.
Publicado: (2023)

Comparative Cost-Effectiveness of Tofacitinib With Continuing Conventional Synthetic Disease-Modifying Anti-Rheumatic Drugs for Active Rheumatoid Arthritis in South Korea
por: Ha, So-Young, et al.
Publicado: (2021)

Healthcare Professionals’ Compliance with the Standard Management Guidelines towards the Use of Biological Disease-Modifying Anti-Rheumatic Drugs in Rheumatoid Arthritis Patients
por: Shakeel, Sadia, et al.
Publicado: (2022)

Differences in trajectory of disease activity according to biologic and targeted synthetic disease-modifying anti-rheumatic drug treatment in patients with rheumatoid arthritis
por: Koo, Bon San, et al.
Publicado: (2022)

Motivations for inadequate persistence with disease modifying anti-rheumatic drugs in early rheumatoid arthritis: the patient’s perspective
por: Pascual-Ramos, Virginia, et al.
Publicado: (2013)

Bone mineral density changes during treatment of rheumatoid arthritis with disease-modifying-anti-rheumatic drugs
por: Heidari, Behzad, et al.
Publicado: (2012)

Gene expression of Interleukin-18 in rheumatoid arthritis patients on disease modifying anti-rheumatic drug therapy
por: Khalid, Sabeen, et al.
Publicado: (2019)

Association between obesity and remission in rheumatoid arthritis patients treated with disease-modifying anti-rheumatic drugs
por: Abuhelwa, Ahmad Y., et al.
Publicado: (2020)

Molecular Changes in the Adipose Tissue Induced by Rheumatoid Arthritis: Effects of Disease-Modifying Anti-Rheumatic Drugs
por: Arias de la Rosa, Iván, et al.
Publicado: (2021)

Effect of glucocorticoids combined with disease modifying anti-rheumatic drugs on the improvement of symptoms in patients with rheumatoid arthritis
por: Si, Lulu, et al.
Publicado: (2022)

Advances in the implications of the gut microbiota on the treatment efficacy of disease-modifying anti-rheumatic drugs in rheumatoid arthritis
por: Fan, Junyu, et al.
Publicado: (2023)

Effect of disease-modifying anti-rheumatic drugs on bone structure and strength in psoriatic arthritis patients
por: Simon, David, et al.
Publicado: (2019)

Periodontal Condition in Patients with Rheumatoid Arthritis: Effect of Anti-rheumatic Drugs
por: Kordtabar, Samira, et al.
Publicado: (2019)

Effect of Anti-Rheumatic Drugs on Cardiovascular Disease Events in Rheumatoid Arthritis
por: Baoqi, Yang, et al.
Publicado: (2022)

Evaluating patient reported outcomes in routine practice of patients with rheumatoid arthritis treated with biological disease modifying anti rheumatic drugs (b-DMARDs)
por: Boone, Niels W., et al.
Publicado: (2015)

Use of biologic or targeted-synthetic disease-modifying anti-rheumatic drugs and risk of diabetes treatment intensification in patients with rheumatoid arthritis and diabetes mellitus
por: Chen, Sarah K, et al.
Publicado: (2020)

Circulating calprotectin (S100A8/A9) is higher in rheumatoid arthritis patients that relapse within 12 months of tapering anti-rheumatic drugs
por: de Moel, Emma C., et al.
Publicado: (2019)

Prediction of remission and low disease activity in disease-modifying anti-rheumatic drug-refractory patients with rheumatoid arthritis treated with golimumab
por: Vastesaeger, Nathan, et al.
Publicado: (2016)

Gout, Rheumatism, and Rheumatoid Arthritis
Publicado: (1900)

Chronic Rheumatism and Rheumatoid Arthritis
por: Lindsay, J.
Publicado: (1908)

Association between biologic disease modifying anti-rheumatic drugs and incident hypertension in patients with rheumatoid arthritis: Results from prospective nationwide KOBIO Registry
por: Kim, Seong-Kyu, et al.
Publicado: (2020)

Biologic and oral disease-modifying antirheumatic drug monotherapy in rheumatoid arthritis
por: Emery, Paul, et al.
Publicado: (2013)

Tuberculosis in Children with Rheumatic Diseases Treated with Biologic Disease-Modifying Anti-Rheumatic Drugs
por: Kavadichanda, Chengappa, et al.
Publicado: (2021)

Rheumatoid arthritis serotype and synthetic disease-modifying anti-rheumatic drugs in patients with periodontitis: A case-control study
por: Nik-Azis, Nik-Madihah, et al.
Publicado: (2021)

Saudi cultural adaptation of the “compliance questionnaire of Rheumatology” for Rheumatoid arthritis patients on disease modifying anti-rheumatic drugs (DMARDs)
por: Aljohani, Roaa, et al.
Publicado: (2021)

The Anxiety and Depression in Rheumatoid Arthritis Patients Treating with Disease-Modifying Anti-Rheumatic Drugs during the COVID-19 Pandemic
por: Sargın, Gökhan, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_rph90a414oitpin8jk3qnjl0js